Compare CDLR & NEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CDLR | NEO |
|---|---|---|
| Founded | 2008 | 2001 |
| Country | Denmark | United States |
| Employees | N/A | N/A |
| Industry | | Precision Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.1B |
| IPO Year | 2023 | 2008 |
| Metric | CDLR | NEO |
|---|---|---|
| Price | $23.00 | $15.90 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $13.38 |
| AVG Volume (30 Days) | 60.4K | ★ 3.0M |
| Earning Date | 05-20-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $53.56 | $10.63 |
| Revenue Next Year | $32.79 | $9.73 |
| P/E Ratio | $7.39 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $15.37 | $5.94 |
| 52 Week High | $30.01 | $16.92 |
| Indicator | CDLR | NEO |
|---|---|---|
| Relative Strength Index (RSI) | 51.30 | 57.99 |
| Support Level | $20.81 | $13.43 |
| Resistance Level | $23.79 | N/A |
| Average True Range (ATR) | 0.37 | 0.69 |
| MACD | 0.04 | -0.01 |
| Stochastic Oscillator | 64.42 | 74.42 |
Cadeler AS is an offshore wind installation vessel contractor. It currently operates various offshore jack-up wind installation vessels, with new builds on order. The Group operates within the market for the transportation and installation of offshore wind turbine generators (WTGs) and their foundations. In addition to wind farm installation, its vessels can perform maintenance, decommissioning, and other general construction tasks within the offshore industry. Cadler's customer base consists of offshore wind farm developers, original equipment manufacturers, and various offshore contractors. Geographically, the Group generates maximum revenue from the United States and the rest from the United Kingdom, Taiwan, Germany, Denmark, Poland, and other regions.
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. The company operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.